{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:36:09Z","timestamp":1791855369147,"version":"4.3.4"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Q Pharma\/Inmunotek Laboratories"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrent urinary tract infections (rUTIs) disproportionately affect older women and are frequently driven by nonmodifiable risk factors (nmRFs). This study evaluated the effectiveness, safety, and patient-reported outcomes (PROs) of personalized sublingual immunoprophylaxis in women with rUTIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, single-center, noncomparative observational cohort study. Women with rUTIs received a Uromune\u00ae autovaccine prepared from inactivated strains isolated from each patient's urine culture (UC). Recurrence episodes and UC results were recorded at baseline and at 3, 9, and 12 months. PROs (daily activity, QAct; emotional distress, QEm) were assessed in a predefined substudy. Longitudinal mixed-effects and population-averaged models evaluated change over time and explored baseline risk factors as effect modifiers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 119 screened women, 100 were enrolled (median [IQR] age: 73 [61\u201380] years); most presented multiple nmRFs. Median (IQR) rUTI episodes decreased from 4 (3\u20135) at baseline to 0 (0\u20132) at 3 months and remained 1 (0\u20132) and 1 (0\u20133) at 9 and 12 months (all P &amp;lt; .001). Approximately 40% were UTI-free in each follow-up interval. UC negativity was 50.7% at 3 months, decreased at 9 months (25.9%), and increased again at 12 months (45.5%), remaining higher than baseline. QEm improved significantly at 3 and 12 months; QAct showed a trend toward improvement. Vaccine-related adverse events were uncommon (6%) and mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Individualized sublingual immunoprophylaxis was safe and associated with sustained reductions in rUTI episodes, improved microbiological findings, and better emotional well-being, suggesting a potential role as a nonantibiotic preventive strategy. These observational findings are hypothesis-generating and warrant confirmation in controlled studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag315","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:32:56Z","timestamp":1779190376000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9734-9334","authenticated-orcid":false,"given":"Vicens","family":"Diaz-Brito","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]},{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-7073","authenticated-orcid":false,"given":"Montserrat","family":"Sanmart\u00ed","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]},{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6684-1394","authenticated-orcid":false,"given":"Araceli","family":"Gonz\u00e1lez-Cuevas","sequence":"additional","affiliation":[{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]},{"name":"Department of Microbiology, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"C\u00e1rdenas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]},{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Guerrero","sequence":"additional","affiliation":[{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]},{"name":"Department of Microbiology, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Capella","sequence":"additional","affiliation":[{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]},{"name":"Department of Pharmacy, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8177-4670","authenticated-orcid":false,"given":"Eva","family":"Mart\u00ednez-Franco","sequence":"additional","affiliation":[{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]},{"name":"Department of Gynecology, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Margarit","sequence":"additional","affiliation":[{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]},{"name":"Department of Gynecology, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7423-8769","authenticated-orcid":false,"given":"Anna","family":"Agud","sequence":"additional","affiliation":[{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]},{"name":"Department of Urology, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Maria","family":"Bastaros","sequence":"additional","affiliation":[{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]},{"name":"Department of Urology, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-0709","authenticated-orcid":false,"given":"Francisco","family":"Medina","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]},{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5008-9088","authenticated-orcid":false,"given":"Encarna","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]},{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5805-3873","authenticated-orcid":false,"given":"Mar\u00eda Carmen","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]},{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3519-1965","authenticated-orcid":false,"given":"Erika","family":"Esteve-Palau","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Parc Sanitari Sant Joan de Deu , Sant Boi (Barcelona) ,","place":["Spain"]},{"name":"Sant Joan de Deu Research Institute , Esplugues (Barcelona) ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026060408242865900_ofag315-B1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"2026060408242865900_ofag315-B2","doi-asserted-by":"crossref","first-page":"888205","DOI":"10.3389\/fpubh.2022.888205","article-title":"Disease burden and long-term trends of urinary tract infections: a worldwide report","volume":"10","author":"Yang","year":"2022","journal-title":"Front Public Health"},{"key":"2026060408242865900_ofag315-B3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40261-013-0069-x","article-title":"An economic perspective on urinary tract infection: the \u201ccosts of resignation","volume":"33","author":"Ciani","year":"2013","journal-title":"Clin Drug Investig"},{"key":"2026060408242865900_ofag315-B4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12913-016-1620-2","article-title":"The economic burden of urinary tract infections in women visiting general practices in France: a cross-sectional survey","volume":"16","author":"Fran\u00e7ois","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"2026060408242865900_ofag315-B5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/jgid.jgid_104_17","article-title":"State of the globe: rising antimicrobial resistance of pathogens in urinary tract infection","volume":"10","author":"Paul","year":"2018","journal-title":"J Glob Infect Dis"},{"key":"2026060408242865900_ofag315-B6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.ju.0000155596.98780.82","article-title":"Urologic diseases in America project: trends in resource use for urinary tract infections in women","volume":"173","author":"Griebling","year":"2005","journal-title":"J Urol"},{"issue":"1A","key":"2026060408242865900_ofag315-B7","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/S0002-9343(02)01054-9","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"113","author":"Foxman","year":"2002","journal-title":"Am J Med"},{"key":"2026060408242865900_ofag315-B8","doi-asserted-by":"crossref","first-page":"1402941","DOI":"10.3389\/fcimb.2024.1402941","article-title":"Comprehensive insights into UTIs: from pathophysiology to precision diagnosis and management","volume":"14","author":"Sujith","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"2026060408242865900_ofag315-B9","volume-title":"EAU guidelines: urological infections 2025. Arnhem, The Netherlands: European Association of Urology","author":"EAU Guidelines Office","year":"2025"},{"key":"2026060408242865900_ofag315-B10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/JU.0000000000000296","article-title":"Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"202","author":"Anger","year":"2019","journal-title":"J Urol"},{"key":"2026060408242865900_ofag315-B11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/JU.0000000000002888","article-title":"Updates to recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline","volume":"208","author":"Bixler","year":"2022","journal-title":"J Urol"},{"key":"2026060408242865900_ofag315-B12","first-page":"Doc01","article-title":"Psychosocial burden of recurrent uncomplicated urinary tract infections","volume":"10","author":"Naber","year":"2022","journal-title":"GMS Infect Dis"},{"key":"2026060408242865900_ofag315-B13","doi-asserted-by":"crossref","first-page":"17455057231216537","DOI":"10.1177\/17455057231216537","article-title":"Psychosocial impact of recurrent urogenital infections: a review","volume":"19","author":"Thomas-White","year":"2023","journal-title":"Womens Health (Lond)"},{"key":"2026060408242865900_ofag315-B14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/life14010106","article-title":"Update on urinary tract infection antibiotic resistance\u2014a retrospective study in females in conjunction with clinical data","volume":"14","author":"Mare\u0219","year":"2024","journal-title":"Life"},{"key":"2026060408242865900_ofag315-B15","doi-asserted-by":"crossref","first-page":"e0196115","DOI":"10.1371\/journal.pone.0196115","article-title":"Value of perioperative genitourinary screening culture and colonization status in predicting early urinary tract infection after renal transplantation","volume":"13","author":"Han","year":"2018","journal-title":"PLoS One"},{"key":"2026060408242865900_ofag315-B16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fmicb.2017.01566","article-title":"UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies","volume":"8","author":"Terlizzi","year":"2017","journal-title":"Front Microbiol"},{"key":"2026060408242865900_ofag315-B17","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.3390\/ijms241310537","article-title":"Urinary tract infections caused by Uropathogenic Escherichia coli: mechanisms of infection and treatment options","volume":"24","author":"Zhou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026060408242865900_ofag315-B18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4103\/UA.UA_104_19","article-title":"Management of urinary tract infection in women: a practical approach for everyday practice","volume":"11","author":"Abou Heidar","year":"2019","journal-title":"Urol Ann"},{"key":"2026060408242865900_ofag315-B19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.mpsur.2020.01.011","article-title":"Pathophysiology of urinary tract infections","volume":"38","author":"Walsh","year":"2020","journal-title":"Surgery (Oxford)"},{"key":"2026060408242865900_ofag315-B20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14787210.2023.2279104","article-title":"Treating urinary tract infections in the era of antibiotic resistance","volume":"21","author":"Frimodt-M\u00f8ller","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026060408242865900_ofag315-B21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/pds.1501","article-title":"Antibiotics in Dutch general practice: nationwide electronic GP database and national reimbursement rates","volume":"17","author":"Akkerman","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026060408242865900_ofag315-B22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5489\/cuaj.6690","article-title":"Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future","volume":"14","author":"Nickel","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"2026060408242865900_ofag315-B23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1473-3099(18)30279-2","article-title":"Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial","volume":"18","author":"Fisher","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026060408242865900_ofag315-B24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/cid\/ciw396","article-title":"Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens","volume":"63","author":"Walker","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026060408242865900_ofag315-B25","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management","volume":"73","author":"Kaye","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026060408242865900_ofag315-B26","author":"European Centre for Disease Prevention and Control and WHO Regional Office for Europe"},{"key":"2026060408242865900_ofag315-B27","volume-title":"Fighting antimicrobial resistance in the EU\/EEA. Embracing a one health approach","author":"Organisation for Economic Co-operation and Development (OECD)","year":"2023"},{"key":"2026060408242865900_ofag315-B28","first-page":"217","article-title":"How to avoid drug resistance during treatment and prevention of urinary tract infections","volume":"20","author":"Warzecha","year":"2021","journal-title":"Prz Menopauzalny"},{"key":"2026060408242865900_ofag315-B29","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jamainternmed.2018.4204","article-title":"Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial","volume":"178","author":"Hooton","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026060408242865900_ofag315-B30","doi-asserted-by":"crossref","first-page":"2042098619876749","DOI":"10.1177\/2042098619876749","article-title":"Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence","volume":"10","author":"Chwa","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"2026060408242865900_ofag315-B31","doi-asserted-by":"crossref","first-page":"e068229","DOI":"10.1136\/bmj-2021-0068229","article-title":"Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial","volume":"376","author":"Harding","year":"2022","journal-title":"BMJ"},{"key":"2026060408242865900_ofag315-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/QOIZ6538","article-title":"Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT","volume":"26","author":"Harding","year":"2022","journal-title":"Health Technol Assess"},{"key":"2026060408242865900_ofag315-B33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00192-020-04397-z","article-title":"Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials","volume":"32","author":"Chen","year":"2021","journal-title":"Int Urogynecol J"},{"key":"2026060408242865900_ofag315-B34","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.juro.2013.04.142","article-title":"Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials","volume":"190","author":"Beerepoot","year":"2013","journal-title":"J Urol"},{"key":"2026060408242865900_ofag315-B35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SPV.0000000000000244","article-title":"Pharmacological agents to decrease new episodes of recurrent lower urinary tract infections in postmenopausal women. A systematic review","volume":"22","author":"Due\u00f1as-Garcia","year":"2016","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"2026060408242865900_ofag315-B36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eururo.2010.12.039","article-title":"Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial","volume":"59","author":"Damiano","year":"2011","journal-title":"Eur Urol"},{"key":"2026060408242865900_ofag315-B37","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00192-012-1794-z","article-title":"Effectiveness of intravesical hyaluronic acid\/chondroitin sulfate in recurrent bacterial cystitis: a randomized study","volume":"23","author":"De Vita","year":"2012","journal-title":"Int Urogynecol J"},{"key":"2026060408242865900_ofag315-B38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00192-017-3508-z","article-title":"Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis","volume":"29","author":"Goddard","year":"2018","journal-title":"Int Urogynecol J"},{"key":"2026060408242865900_ofag315-B39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12894-021-00811-w","article-title":"High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial","volume":"21","author":"Babar","year":"2021","journal-title":"BMC Urol"},{"key":"2026060408242865900_ofag315-B40","doi-asserted-by":"crossref","first-page":"e7185","DOI":"10.5867\/medwave.2018.02.7185","article-title":"Are probiotics effective in preventing urinary tract infection?","volume":"18","author":"Canales","year":"2018","journal-title":"Medwave"},{"key":"2026060408242865900_ofag315-B41","first-page":"CD013608","article-title":"D-mannose for preventing and treating urinary tract infections","volume":"8","author":"Cooper","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026060408242865900_ofag315-B42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/jmwh.12472","article-title":"Probiotics for treatment and prevention of urogenital infections in women: a systematic review","volume":"61","author":"Hanson","year":"2016","journal-title":"J Midwifery Womens Health"},{"key":"2026060408242865900_ofag315-B43","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.euf.2020.09.004","article-title":"Role of D-mannose in the prevention of recurrent urinary tract infections: evidence from a systematic review of the literature","volume":"7","author":"Kyriakides","year":"2021","journal-title":"Eur Urol Focus"},{"key":"2026060408242865900_ofag315-B44","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.ajog.2020.05.048","article-title":"D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis","volume":"223","author":"Lenger","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"2026060408242865900_ofag315-B45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3945\/an.115.011197","article-title":"Cranberries and urinary tract infections: how can the same evidence lead to conflicting advice?","volume":"7","author":"Liska","year":"2016","journal-title":"Adv Nutr"},{"key":"2026060408242865900_ofag315-B46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrurol.2011.72","article-title":"Lactobacillus probiotic could prevent recurrent UTI","volume":"8","author":"Ray","year":"2011","journal-title":"Nat Rev Urol"},{"key":"2026060408242865900_ofag315-B47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.euf.2024.04.002","article-title":"Bacterial vaccines for the management of recurrent urinary tract infections: a systematic review and meta-analysis","volume":"10","author":"Mak","year":"2024","journal-title":"Eur Urol Focus"},{"key":"2026060408242865900_ofag315-B48","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.euf.2019.11.002","article-title":"Role of vaccines for recurrent urinary tract infections: a systematic review","volume":"6","author":"Prattley","year":"2020","journal-title":"Eur Urol Focus"},{"key":"2026060408242865900_ofag315-B49","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/mi.2016.112","article-title":"MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88","volume":"10","author":"Benito-Villalvilla","year":"2017","journal-title":"Mucosal Immunol"},{"key":"2026060408242865900_ofag315-B50","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000505162","article-title":"Analysis of the efficacy of a sublingual bacterial vaccine in the prophylaxis of recurrent urinary tract infection","volume":"104","author":"Carri\u00f3n-L\u00f3pez","year":"2020","journal-title":"Urol Int"},{"key":"2026060408242865900_ofag315-B51","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JU.0000000000003969","article-title":"It's time to embrace vaccination as we enter the postantibiotic era of recurrent urinary tract infection management","volume":"211","author":"Doiron","year":"2024","journal-title":"J Urol"},{"key":"2026060408242865900_ofag315-B52","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/vaccines12121426","article-title":"Immunoprophylaxis with MV140 is effective in the reduction of urinary tract infections\u2014a prospective real-life study","volume":"12","author":"Lopes","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026060408242865900_ofag315-B53","doi-asserted-by":"crossref","first-page":"EVIDoa2100018","DOI":"10.1056\/EVIDoa2100018","article-title":"Sublingual MV140 for prevention of recurrent urinary tract infections","volume":"1","author":"Lorenzo-G\u00f3mez","year":"2022","journal-title":"NEJM Evid"},{"key":"2026060408242865900_ofag315-B54","doi-asserted-by":"crossref","first-page":"1066383","DOI":"10.3389\/fimmu.2022.1066383","article-title":"Candida albicans V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections","volume":"13","author":"Mart\u00edn-Cruz","year":"2022","journal-title":"Front Immunol"},{"key":"2026060408242865900_ofag315-B55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2008.08.011","article-title":"Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis","volume":"33","author":"Naber","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2026060408242865900_ofag315-B56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euros.2024.03.010","article-title":"Reducing recurrent urinary tract infections in women with MV140 impacts personal burden of disease: secondary analyses of a randomized placebo-controlled efficacy study","volume":"63","author":"Nickel","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"2026060408242865900_ofag315-B57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/pathogens12030359","article-title":"An effective sublingual vaccine, MV140, safely reduces risk of recurrent urinary tract infection in women","volume":"12","author":"Nickel","year":"2023","journal-title":"Pathogens"},{"key":"2026060408242865900_ofag315-B58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/bju.14067","article-title":"First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune","volume":"121","author":"Yang","year":"2018","journal-title":"BJU Int"},{"key":"2026060408242865900_ofag315-B59","first-page":"25","article-title":"MV140 sublingual vaccine reduces recurrent urinary tract infection in women results from the first North American clinical experience study","volume":"18","author":"Nickel","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"2026060408242865900_ofag315-B60","first-page":"464","article-title":"Immunoactive prophylaxis protocol of uncomplicated recurrent urinary tract infections in a cohort of 1104 women treated with uromune\u00ae vaccine","volume":"14","author":"Ram\u00edrez Sevilla","year":"2024","journal-title":"Life (Basel)"},{"key":"2026060408242865900_ofag315-B61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12879-025-10524-2","article-title":"Evaluating the use of Uromune\u00ae autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain","volume":"25","author":"Iftimie","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2026060408242865900_ofag315-B62","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1016\/j.vaccine.2021.08.093","article-title":"Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly","volume":"39","author":"Lorenzo-G\u00f3mez","year":"2021","journal-title":"Vaccine"},{"key":"2026060408242865900_ofag315-B63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.acuro.2022.05.007","article-title":"Effectiveness and health cost analysis between immunoprophylaxis with MV140 autovaccine, MV140 vaccine and continuous treatment with antibiotics to prevent recurrent urinary tract infections","volume":"47","author":"Ram\u00edrez-Sevilla","year":"2023","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"2026060408242865900_ofag315-B64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/nau.20017","article-title":"Validity and reliability of a questionnaire to measure the impact of lower urinary tract symptoms on quality of life: the Leicester impact scale","volume":"23","author":"Shaw","year":"2004","journal-title":"Neurourol Urodyn"},{"key":"2026060408242865900_ofag315-B65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"2026060408242865900_ofag315-B66","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","article-title":"Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers","volume":"8","author":"Atkinson","year":"2005","journal-title":"Value Health"},{"key":"2026060408242865900_ofag315-B67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/vaccines12050535","article-title":"MV140 mucosal vaccine induces targeted immune response for enhanced clearance of uropathogenic E. coli in experimental urinary tract infection","volume":"12","author":"Saz-Leal","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026060408242865900_ofag315-B68","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1159\/000521772","article-title":"Cost-effectiveness of a sublingual bacterial vaccine for the prophylaxis of recurrent urinary tract infections","volume":"106","author":"Carri\u00f3n-L\u00f3pez","year":"2022","journal-title":"Urol Int"},{"key":"2026060408242865900_ofag315-B69","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026060408242865900_ofag315-B70","volume-title":"Antibiotic use and stewardship in the United States, 2025 update: progress and opportunities","author":"Centers for Disease Control and Prevention (CDC)","year":"2025"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag315\/68363424\/ofag315.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag315\/68363424\/ofag315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag315\/68363424\/ofag315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:24:40Z","timestamp":1780575880000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag315\/8690139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag315","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,21]]},"article-number":"ofag315"}}